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Amyotrophic lateral sclerosis (ALS) is usually sporadic, but 5%-10% of patients have a hereditary form of the disease. About 20% of familial patients have mutations in the SOD1 gene, 1 and recently other gene mutations have been found in familial ALS: TDP-43, FUS, and VCP. [2] [3] [4] [5] Interestingly, the protein products of 2 of these genes, TDP-43 and FUS, are likely involved in RNA metabolism. TDP-43 forms cytoplasmic inclusions in neurons of patients with both sporadic and familial ALS and frontotemporal dementia.
Genetic risk factors may play a role in sporadic as well as familial ALS, but the results of association studies have been mixed. For example, the gene for the neurotrophic factor VEGF is a possible risk factor in various European populations, 6 but studies in other populations did not confirm the finding. 7 It is now clear that there is no genetic risk factor for ALS as strong as APOE is for Alzheimer disease, and finding and confirming weaker risk factors requires large studies in multiple populations with well-matched controls.
Several months ago, Elden and colleagues 8 reported a novel risk factor for ALS in ATXN2, the gene for the polyglutamine expansion neurodegenerative disease spinocerebellar ataxia 2 (SCA2). This gene showed up in a screen for modifiers of TDP-43 toxicity in yeast and has a similar effect in Drosophila. 8 TDP-43 and ataxin 2 interact in an RNAdependent manner. Perhaps most importantly for the human disease connection, more than twice as many patients with ALS as controls had ataxin 2 polyglutamine repeat lengths in the high normal range (Ն24 glutamines). The ratio was even greater with repeat lengths Ն27 glutamines, close to the range associated with SCA2 (Ն33). If confirmed, this would mean that ATXN2 is the most common genetic risk factor for ALS identified to date.
In the current issue of Neurology ® , Van Damme and colleagues 9 extend the analysis of ATXN2 to a larger cohort of Dutch and Belgian patients with ALS and controls. The results support the previously reported American findings, with an interesting twist. The association of ALS with ATXN2 was only found with longer repeat lengths (Ն29), and it was found in familial as well as sporadic ALS. The disease manifestations in patients with long ATXN2 repeats ranged from typical, rapidly progressive ALS to a disorder with earlier onset, slower progression, and sensory involvement. In at least some of these patients, there is clinical overlap between ALS and SCA2, i.e., SCA2 may be presenting as a motor neuron disease with features of ALS, as has been reported previously. 10 Such clinical overlap has been reported previously between SCA2 and Parkinson disease, 11 and between ALS and spinal and bulbar muscular atrophy (SBMA, Kennedy disease). 12 Many patients with SBMA are initially diagnosed with ALS because both disorders cause progressive weakness due to motor neuron degeneration, although the disease course and other clinical features are generally different.
Could the apparent increase in risk of ALS with long ATXN2 repeats be simply due to the misclassification of SCA2 as ALS? Van Damme et al. argue not for various reasons, including the presence of long ATXN2 repeats in patients with sporadic ALS with a typical disease presentation and the observation that SCA2 can present with a pure motor neuron degeneration phenotype. 9 However, neither study found an association of ALS with ATXN2 repeat length overall, only at the longer end of the repeat range 8, 9 ; this may explain why this locus has not appeared in genome-wide association studies of ALS. 13 Also, increased instability of the repeat might make it difficult to detect this association even with directly adjacent genetic markers. Further studies in well-characterized ALS populations with well-matched controls should help to settle whether ATXN2 repeat length is truly a risk factor for ALS. A study by Lee and colleagues 14 in the current issue of Neurology ® did not find an association of ALS with long repeats in other polyglutamine disease genes (the SBMA gene was not included).
Association studies with genes containing multiple variants are challenging. Given the range of different repeat lengths in the ATXN2 gene, the authors tried to circumvent this problem by defining repeat classes. As this was done post hoc in both articles, stringent significance testing may be difficult to apply. As both groups apply different cutoffs to construct repeat classes, the association data remain inconclusive.
Despite these potential shortcomings, both studies demonstrate that expansion of the ATXN2 repeat to pathologic sizes of Ն32 can be associated with a clinical phenotype dominated by motor neuron disease. Van Damme and coworkers point out that appearance of cerebellar dysfunction in these patients can be delayed by up to 2 decades.
It remains unknown why pathologic expansion of Ն32 repeats in the ATXN2 gene most commonly leads to cerebellar degeneration, but to a Parkinson disease or ALS-like phenotype in occasional individuals. Environmental or genetic factors can affect the phenotype of neurodegenerative diseases. The cluster of ALS-like manifestations in 2 pedigrees is consistent with effects of genetic background and perhaps genetic variants within or close to the ATXN2 gene. The presence of interruptions in the expanded repeat has been suggested as a cause of the Parkinson-like phenotype seen with ATXN2 mutations. 15 The take-home lesson for neurologists is to be aware that ALS and SCA2 can have partially overlapping clinical features. Accurate diagnosis has important implications for a patient's prognosis and the risk to family members. The overlap in clinical manifestations also indicates an overlap in the disease mechanisms, with common features of toxic proteins prone to aggregation, mislocalization, and aberrant interactions that ultimately lead to motor neuron dysfunction and death. And an overlap in the mechanisms suggests that a common approach to treatment may be successful. Neurology, 2nd-5th (AAN Press, 1996) ; serves on the speakers' bureau for Athena Diagnostics, Inc.; receives research support from the NIH/NINDS; and has received license fee payments from Cedars-Sinai Medical Center.
